European Journal of Pharmacology, 191 (1990) 507–510
Elsevier

Author index

Abbate, G.M., see Schmidt, C.J. (191) 213
Ahrén, B., see Karlsson, S. (191) 457
Al-Tajir, G. and Starr, M.S.
Anticonvulsant action of SCH 23390 in the striatum of the rat (191) 329
Albuquerque, E.X., see Alkondon, M. (191) 505
Alkondon, M. and Albuquerque, E.X.
α-Cobratoxin blocks the nicotinic acetylcholine receptor in rat hippocampal neurons (191) 505
Amiranoff, B., Lorinet, A.-M. and Laburthe, M.
Galanin inhibits somatostatin release by the rat islet cell tumor in culture, Rin-m (191) 401
Autore, G., Caliendo, G., Pepe, A. and Capasso, F.
Perfusion of rat colon with sennosides, rhein and rheinanthrone. Concentration-related histamine release (191) 97
Ayajiki, K. and Toda, N.
Isolated bovine cerebral arteries from rostral and caudal regions: distinct responses to adrenoceptor agonists (191) 417

Bandelier, V., see Steulet, A.-F. (191) 19
Barer, G.R., see Liu, S. (191) 345
Barnes, P.J., see Liu, S. (191) 345
Beart, P.M., see Carlberg, M. (191) 107
Benedetti, M., see Popoli, P. (191) 141
Bernasconi, R., see Steulet, A.-F. (191) 19
Bervoets, K., Millan, M.J. and Colpaert, F.C.
Agonist action at 5-HT_{1C} receptors facilitates 5-HT_{1A} receptor-mediated spontaneous tail-flicks in the rat (191) 185
Bhandare, P., Diniz-D'Souza, R., Mainker, A. and Dhume, V.
Protective effect of propranolol on ethanol-induced gastric lesions in mice (191) 167
Bischoff, S., see Steulet, A.-F. (191) 19
Black, C.K., see Schmidt, C.J. (191) 213
Boselli, C. and Kenakin, T.P.
Promiscuous or heterogeneous muscarinic receptors in rat atria? II. Antagonism of responses to carbachol by pirenzepine (191) 49
Boselli, C., see Kenakin, T.P. (191) 39
Bottari, S., see Tence, M. (191) 427
Boughton-Smith, N.K., Hutcheson, I.R., Deakin, A.M., Whittle, B.J.R. and Moncada, S.
Protective effect of S-nitroso-N-acetyl-penicillamine in endotoxin-induced acute intestinal damage in the rat (191) 485
Brain, S.D., see Hughes, S.R. (191) 481
Brooderson, R.J., see White, F.J. (191) 497
Brugger, F., Wicki, U., Nassenstein-Elton, D., Fagg, G.E., Olpe, H.-R. and Pozza, M.F.
Modulation of the NMDA receptor by D-serine in the cortex and the spinal cord, in vitro (191) 29
Brunswick, D.J., see Tejani-Butt, S.M. (191) 239
Burks, T.F., see Davis, T.P. (191) 253

Cai, Y., see Liu, S. (191) 345
Caliendo, G., see Autore, G. (191) 97
Canton, H., Verrièle, L. and Colpaert, F.C.
Binding of typical and atypical antipsychotics to 5-HT_{1C} and 5-HT_2 sites: clozapine potently interacts with 5-HT_{1C} sites (191) 93
Capasso, F., see Autore, G. (191) 97
Carlberg, M., Beart, P.M. and Jarrott, B.
[^{125}I][D-Tyr^{25},Nle28,31]CCK-(25-33): a convenient new aminopeptidase resistant cholecystokinin analogue for radioligand binding and autoradiography (191) 107
Chan, C.-C., McKee, K., Tagari, P., Chee, P. and Ford-Hutchinson, A.
Eosinophil-eicosanoid interactions: inhibition of eosinophil chemotaxis in vivo by a LTD_4-receptor antagonist (191) 273
Chee, P., see Chan, C.-C. (191) 273
Chiba, S. and Tsukada, M.
Predominant acetylcholine-induced vasoconstriction in isolated, perfused simian facial veins (191) 311
Colpaert, F.C., see Bervoets, K. (191) 185
Colpaert, F.C., see Canton, H. (191) 93
Cowen, P.J., see Gartside, S.E. (191) 391
Culling-Berglund, A., see Konings, P.N.M. (191) 115

Davis, P., see Davis, T.P. (191) 253
Davis, T.P., Hoyer, G.L., Davis, P. and Burks, T.F.
Proenkephalin A-derived peptide E and its fragments alter opioid contractility in the small intestine (191) 253
Davis, T.P., see Konings, P.N.M. (191) 115
Deakin, A.M., see Boughton-Smith, N.K. (191) 485
Del Monte, F., see Jones, S.M. (191) 129
De Wildt, D.J., see Verrijk, R. (191) 197
Dhume, V., see Bhandare, P. (191) 167
Diaz-Toledo, A. and Jurkiewicz, A.
Dissociation constants and relative efficacies estimated from the functional antagonism of β-adrenoceptor agonists on transmural stimulation in rat vas deferens (191) 157
Dickenson, A., see Haley, J. (191) 437
Diniz-D'Souza, R., see Bhandare, P. (191) 167

0014-2999/90/$03.50 © 1990 Elsevier Science Publishers B.V. (Biomedical Division)

Di Somma, M., see Patrignani, P. (191) 83
Dockray, G.J., see Forster, E.R. (191) 235
Doi, T., see Hasegawa, J. (191) 369
Dumont, Y., Fournier, A., St-Pierre, S., Schwartz, T.W. and Quirion, R.
Differential distribution of neuropeptide Y_1 and Y_2 receptors in the rat brain (191) 501
Dürmüller, N., see Smith, S.E. (191) 337
Dzwonczyk, S., see Grover, G.J. (191) 11

Edvinsson, L., see Horsburgh, K. (191) 205
Escorihuela, R.M., see Fernández-Teruel, A. (191) 111
Estan, L., see Senard, J.M. (191) 59
Evans, A.M. and Green, K.L.
The effect of domperidone on the electrical response of cockroach salivary gland acinar cells (191) 465
Evans, T.W., see Liu, S. (191) 345

Fagg, G.E., see Brugger, F. (191) 29
Fernández-Teruel, A., Escorihuela, R.M., Jiménez, P. and Tobeña, A.
Infantile stimulation and perinatal administration of Ro 15-1788: additive anxiety-reducing effects in rats (191) 111
Ferrario, R., see Patrignani, P. (191) 83
Fink, K. and Göthert, M.
Inhibition of N-methyl-D-aspartate-induced noradrenaline release by alcohols is related to their hydrophobicity (191) 225
Fitzgerald, J.L. and Reid, J.J.
Effects of methylenedioxymethamphetamine on the release of monoamines from rat brain slices (191) 217
Fleming, I., see Gray, G.A. (191) 89
Ford-Hutchinson, A., see Chan, C.-C. (191) 273
Forster, E.R. and Dockray, G.J.
The effect of ondansetron on gastric emptying in the conscious rat (191) 235
Fournier, A., see Dumont, Y. (191) 501
Franco-Cereceda, A., see Hemsén, A. (191) 319
Frazer, A., see Tejani-Butt, S.M. (191) 239

Gartside, S.E., Cowen, P.J. and Hjorth, S.
Effects of MDL 73005EF on central pre- and postsynaptic 5-HT_{1A} receptor function in the rat in vivo (191) 391
Goldstein, M., see Tsuda, K. (191) 101
Göthert, M., see Fink, K. (191) 225
Gray, G.A., Julou-Schaeffer, G., Oury, K., Fleming, I., Parratt, J.R. and Stoclet, J.-C.
An L-arginine-derived factor mediates endotoxin-induced vascular hyposensitivity to calcium (191) 89
Green, K.L., see Evans, A.M. (191) 465
Grover, G.J., Dzwonczyk, S. and Sleph, P.G.
Reduction of ischemic damage in isolated rat hearts by the potassium channel opener, RP 52891 (191) 11
Grünenwald, C., see Steulet, A.-F. (191) 19
Guillon, G., see Tence, M. (191) 427

Haley, J., Ketchum, S. and Dickenson, A.
Peripheral κ-opioid modulation of the formalin response: an electrophysiological study in the rat (191) 437
Hao, J., Wiesenfeld-Hallin, Z. and Xu, X.
Depression of the flexor reflex by systemic morphine increases in chronically spinalized rats (191) 407
Harding, S.E., see Jones, S.M. (191) 129
Hasegawa, J., Noguchi, N., Sawaguchi, M., Doi, T., Hisatome, I., Kotake, H. and Mashiba, H.
Bunazosin induces use-dependent slowing of conduction in guinea-pig ventricular myocardium (191) 369
Haslam, R.J., see Maurice, D.H. (191) 471
Heinrich, M., see Steulet, A.-F. (191) 19
Hemsén, A., Franco-Cereceda, A., Matran, R., Rudehill, A. and Lundberg, J.M.
Occurrence, specific binding sites and functional effects of endothelin in human cardiopulmonary tissue (191) 319
Herman, A.G., see Verbeuren, T.J. (191) 173
Hisatome, I., see Hasegawa, J. (191) 369
Hjorth, S., see Gartside, S.E. (191) 391
Hollenberg, M.D., see Yamaguchi, K. (191) 245
Horsburgh, K., Jansen, I., Edvinsson, L. and McCulloch, J.
Second messenger systems: functional role in cerebrovascular smooth muscle regulation (191) 205
Hoyer, G.L., see Davis, T.P. (191) 253
Hu, X.-T., see White, F.J. (191) 497
Huang, X., see Johnson, M.P. (191) 1
Hughes, J., see Singh, L. (191) 477
Hughes, S.R., Williams, T.J. and Brain, S.D.
Evidence that endogenous nitric oxide modulates oedema formation induced by substance P (191) 481
Hunt, N.A., see Jones, S.M. (191) 129
Hunter, J.C., see Singh, L. (191) 477
Hutcheson, I.R., see Boughton-Smith, N.K. (191) 485

Jackson, B., see Kidwell, D. (191) 489
Jansen, I., see Horsburgh, K. (191) 205
Jard, S., see Tence, M. (191) 427
Jarrott, B., see Carlberg, M. (191) 107
Jiménez, P., see Fernández-Teruel, A. (191) 111
Johnson, M.P., Huang, X., Oberlender, R., Nash, J.F. and Nichols, D.E.
Behavioral, biochemical and neurotoxicological actions of the α-ethyl homologue of p-chloroamphetamine (191) 1
Jones, S.M., Hunt, N.A., Del Monte, F. and Harding, S.E.
Contraction of cardiac myocytes from noradrenaline-treated rats in response to isoprenaline, forskolin and dibutyryl cAMP (191) 129
Jordaens, F.H., see Verbeuren, T.J. (191) 173
Julou-Schaeffer, G., see Gray, G.A. (191) 89
Jurkiewicz, A., see Diaz-Toledo, A. (191) 157

Kalkman, H.O. and Soar, J.
Determination of the 5-HT receptor subtype involved in 8-OH-DPAT-induced hyperlocomotion: potential difficulties arising from inadequate pharmacological tools (191) 383
Karlsson, S. and Ahrén, B.
Peptide receptor antagonists in the study of insulin and glucagon secretion in mice (191) 457

Kenakin, T.P. and Boselli, C.
Promiscuous or heterogeneous muscarinic receptors in rat atria? I. Schild analysis with simple competitive antagonists (191) 39
Kenakin, T.P., see Boselli, C. (191) 49
Ketchum, S., see Haley, J. (191) 437
Kidwell, D., Subramaniam, S., Ott, C. and Jackson, B.
Impaired cyclic AMP generation in outer medullary tubules of gentamicin-treated rats (191) 489
King, R.G., see Rawlow, A. (191) 263
Kohno, S., see Tsuru, H. (191) 447
Koltai, M., see Tosaki, A. (191) 69
Konings, P.N.M., Culling-Berglund, A. and Davis, T.P.
Chronic haloperidol and chlorpromazine treatment alters in vitro β-endorphin metabolism in rat brain (191) 115
Kotake, H., see Hasegawa, J. (191) 369

Laburthe, M., see Amiranoff, B. (191) 401
Langin, D., see Senard, J.M. (191) 59
Lederis, K., see Yamaguchi, K. (191) 245
Leonhardt, T., see Steulet, A.-F. (191) 19
Li, C.G. and Rand, M.J.
Nitric oxide and vasoactive intestinal polypeptide mediate non-adrenergic, non-cholinergic inhibitory transmission to smooth muscle of the rat gastric fundus (191) 303
Liu, S., Cai, Y., Evans, T.W., McCormack, D.G., Barer, G.R. and Barnes, P.J.
Ligustrazine is a vasodilator of human pulmonary and bronchial arteries (191) 345
Lorinet, A.-M., see Amiranoff, B. (191) 401
Lundberg, J.M., see Hemsén, A. (191) 319
Luo, Q., see Van Heuven-Nolsen, D. (191) 375

Mainker, A., see Bhandare, P. (191) 167
Maître, L., see Steulet, A.-F. (191) 19
Martin, P., see Steulet, A.-F. (191) 19
Mashiba, H., see Hasegawa, J. (191) 369
Masuyama, Y., see Tsuda, K. (191) 101
Matran, R., see Hemsén, A. (191) 319
Matsubayashi, H., see Tsuru, H. (191) 447
Maurice, D.H. and Haslam, R.J.
Nitroprusside enhances isoprenaline-induced increases in cAMP in rat aortic smooth muscle (191) 471
McCormack, D.G., see Liu, S. (191) 345
McCulloch, J., see Horsburgh, K. (191) 205
McKee, K., see Chan, C.-C. (191) 273
Merali, Z. and Piggins, H.
Effects of dopamine D_1 and D_2 receptor agonists and antagonists on bombesin-induced behaviors (191) 281
Millan, M.J., see Bervoets, K. (191) 185
Moncada, S., see Boughton-Smith, N.K. (191) 485

Nakajima, M. and Ueda, M.
Regional differences in the prostanoid receptors mediating prostaglandin $F_{2\alpha}$-induced contractions of cat isolated arteries (191) 359
Nash, J.F., see Johnson, M.P. (191) 1
Nassenstein-Elton, D., see Brugger, F. (191) 29
Nichols, D.E., see Johnson, M.P. (191) 1
Noguchi, N., see Hasegawa, J. (191) 369
Novosad, E.I., see Opgenorth, T.J. (191) 351

Oberlender, R., see Johnson, M.P. (191) 1
Olpe, H.-R., see Brugger, F. (191) 29
Onodera, S., see Takashio, T. (191) 493
Opgenorth, T.J. and Novosad, E.I.
Atrial natriuretic factor and endothelin interactions in control of vascular tone (191) 351
Ott, C., see Kidwell, D. (191) 489
Oury, K., see Gray, G.A. (191) 89

Paris, H., see Senard, J.M. (191) 59
Parratt, J.R., see Gray, G.A. (191) 89
Patrignani, P., Volpi, D., Ferrario, R., Romanzini, L., Di Somma, M. and Patrono, C.
Effects of racemic, S- and R-indobufen on cyclooxygenase and lipoxygenase activities in human whole blood (191) 83
Patrono, C., see Patrignani, P. (191) 83
Paubert-Braquet, M., see Tosaki, A. (191) 69
Pepe, A., see Autore, G. (191) 97
Pierce, R.C. and Rebec, G.V.
Stimulation of both D_1 and D_2 dopamine receptors increases behavioral activation and ascorbate release in the neostriatum of freely moving rats (191) 295
Piggins, H., see Merali, Z. (191) 281
Pittaluga, A. and Raiteri, M.
Release-enhancing glycine-dependent presynaptic NMDA receptors exist on noradrenergic terminals of hippocampus (191) 231
Popoli, P., Benedetti, M. and Scotti de Carolis, A.
Influence of nimodipine and diltiazem, alone and in combination, on phencyclidine-induced effects in rats: an EEG and behavioural study (191) 141
Porsius, A.J., see Verrijk, R. (191) 197
Pozza, M.F., see Brugger, F. (191) 29

Quirion, R., see Dumont, Y. (191) 501

Raiteri, M., see Pittaluga, A. (191) 231
Rand, M.J., see Li, C.G. (191) 303
Rawlow, A. and King, R.G.
A novel in vivo test for drugs affecting central serotonergic and adrenergic systems (191) 263
Rebec, G.V., see Pierce, R.C. (191) 295
Reid, J.J., see Fitzgerald, J.L. (191) 217
Roeder, T.
High-affinity antagonists of the locust neuronal octopamine receptor (191) 221
Romanzini, L., see Patrignani, P. (191) 83
Rudehill, A., see Hemsén, A. (191) 319

Sawaguchi, M., see Hasegawa, J. (191) 369
Saxena, P.R., see Van Heuven-Nolsen, D. (191) 375

Schmidt, C.J., Black, C.K., Abbate, G.M. and Taylor, V.L.
Chloral hydrate anesthesia antagonizes the neurotoxicity of 3,4-methylenedioxymethamphetamine (191) 213
Schwartz, T.W., see Dumont, Y. (191) 501
Scotti de Carolis, A., see Popoli, P. (191) 141
Senard, J.M., Langin, D., Estan, L. and Paris, H.
Identification of α_2-adrenoceptors and non-adrenergic idazoxan binding sites in rabbit colon epithelial cells (191) 59
Singh, L., Vass, C.A., Hunter, J.C., Woodruff, G.N. and Hughes, J.
The anticonvulsant action of CI-977, a selective κ-opioid receptor agonist: a possible involvement of the glycine/NMDA receptor complex (191) 477
Sleph, P.G., see Grover, G.J. (191) 11
Smith, S.E. and Dürmüller, N.
Inositolhexakisphosphate is convulsant in mice and rats in the nanomolar range (191) 337
Soar, J., see Kalkman, H.O. (191) 383
St-Pierre, S., see Dumont, Y. (191) 501
Starr, M.S., see Al-Tajir, G. (191) 329
Steulet, A.-F., Bernasconi, R., Leonhardt, T., Martin, P., Grünenwald, C., Bischoff, S., Heinrich, M., Bandelier, V. and Maître, L.
Effects of selective dopamine D_1 and D_2 receptor agonists on the rate of GABA synthesis in mouse brain (191) 19
Stoclet, J.-C., see Gray, G.A. (191) 89
Subramaniam, S., see Kidwell, D. (191) 489
Sumi, T., see Umeda, Y. (191) 149

Tagari, P., see Chan, C.-C. (191) 273
Takashio, T., Yamashita, H. and Onodera, S.
Pindolol inhibits the development of hypoxic pulmonary vasoconstriction (191) 493
Taylor, V.L., see Schmidt, C.J. (191) 213
Tejani-Butt, S.M., Brunswick, D.J. and Frazer, A.
[^{3}H]Nisoxetine: a new radioligand for norepinephrine uptake sites in brain (191) 239
Tence, M., Guillon, G., Bottari, S. and Jard, S.
Labelling of vasopressin and oxytocin receptors from the human uterus (191) 427
Tobeña, A., see Fernández-Teruel, A. (191) 111
Toda, N., see Ayajiki, K. (191) 417
Tosaki, A., Koltai, M. and Paubert-Braquet, M.
Effect of iloprost on reperfusion-induced arrhythmias and myocardial ion shifts in isolated rat hearts (191) 69
Tsuda, K., Tsuda, S., Goldstein, M. and Masuyama, Y.
Effects of calcitonin gene-related peptide on [^{3}H]norepinephrine release in medulla oblongata of spontaneously hypertensive rats (191) 101
Tsuda, S., see Tsuda, K. (191) 101
Tsukada, M., see Chiba, S. (191) 311
Tsuru, H., Kohno, S. and Matsubayashi, H.
Relaxation response of isolated canine veins to agents that act on the adenylate cyclase-cyclic AMP system: further investigation (191) 447
Tysse Klasen, T.H.M., see Van Heuven-Nolsen, D. (191) 375

Ueda, M., see Nakajima, M. (191) 359
Umeda, Y. and Sumi, T.
Decrease in the evoked release of endogenous dopamine and dihydroxyphenylacetic acid from rat striatal slices after withdrawal from repeated haloperidol (191) 149

Van Heuven-Nolsen, D., Tysse Klasen, T.H.M., Luo, Q. and Saxena, P.R.
5-HT_1-like receptors mediate contractions of the rabbit saphenous vein (191) 375
Van Hove, C.E., see Verbeuren, T.J. (191) 173
Van Hoydonck, A.-E., see Verbeuren, T.J. (191) 173
Van Rooij, H.H., see Verrijk, R. (191) 197
Vass, C.A., see Singh, L. (191) 477
Verbeuren, T.J., Jordaens, F.H., Van Hove, C.E., Van Hoydonck, A.-E. and Herman, A.G.
Release and vascular activity of endothelium-derived relaxing factor in atherosclerotic rabbit aorta (191) 173
Verrièle, L., see Canton, H. (191) 93
Verrijk, R., De Wildt, D.J., Van Rooij, H.H., Wemer, J. and Porsius, A.J.
Cardiovascular responses to milrinone in pertussis toxin-pretreated pithed rats (191) 197
Volpi, D., see Patrignani, P. (191) 83

Wemer, J., see Verrijk, R. (191) 197
White, F.J., Hu, X.-T. and Brooderson, R.J.
Repeated stimulation of dopamine D_1 receptors enhances the effects of dopamine receptor agonists (191) 497
Whittle, B.J.R., see Boughton-Smith, N.K. (191) 485
Wicki, U., see Brugger, F. (191) 29
Wiesenfeld-Hallin, Z., see Hao, J. (191) 407
Williams, T.J., see Hughes, S.R. (191) 481
Woodruff, G.N., see Singh, L. (191) 477

Xu, X., see Hao, J. (191) 407

Yamaguchi, K., Lederis, K. and Hollenberg, M.D.
Contraction of porcine ocular ciliary muscle by epidermal growth factor-urogastrone (191) 245
Yamashita, H., see Takashio, T. (191) 493

European Journal of Pharmacology, 191 (1990) 511–522
Elsevier

Key word index

Acetylcholine
Facial vein (simian); Cannula insertion method; Muscarinic receptor subtypes; Vasoconstriction (Chiba, S. (191) 311)

ACTH (adrenocorticotropin)
MDL 73005EF (8-[2-(2,3-dihydro-1,4-benzodioxin-2-yl)methylamino]-8-azaspiro[4,5]decan-7,9-dione methyl sulphonate); 5-HT_{1A} receptors; 5-HT release; Microdialysis (brain, in vivo); Radioimmunoassay (Gartside, S.E. (191) 391)

Adenosine 3′,5′-cyclic monophosphate
Aminoglycosides; [Arg^8]vasopressin (AVP); Collecting tubule; Henle's loop (thick ascending limb of) (Kidwell, D. (191) 489)

Adenylate cyclase
β-Adrenoceptors; Desensitisation; Myocytes; Noradrenaline (Jones, S.M. (191) 129)

Adenylate cyclase-cyclic AMP system
Vasorelaxation; Precontraction levels; Methoxamine; (Canine veins) (Tsuru, H. (191) 447)

α-Adrenoceptor antagonists
5-HT_{1A} receptors; Locomotion; β-Adrenoceptor antagonists; Dopamine receptors (Kalkman, H.O. (191) 383)

α_1-Adrenoceptor antagonists
Use-dependent block; Conduction velocity; Bunazosin; Antiarrhythmic effect (Hasegawa, J. (191) 369)

β-Adrenoceptor antagonists
5-HT_{1A} receptors; Locomotion; α-Adrenoceptor antagonists; Dopamine receptors (Kalkman, H.O. (191) 383)

Adrenoceptor function (heterogeneity of)
Cerebral artery (bovine); Prazosin; Yohimbine; α_1-Adrenoceptors (Ayajiki, K. (191) 417)

Adrenoceptors
Octopamine receptors; (Insect); (Locust) (Roeder, T. (191) 221)

α_1-Adrenoceptors
Cerebral artery (bovine); Adrenoceptor function (heterogeneity of); Prazosin; Yohimbine (Ayajiki, K. (191) 417)

α_2-Adrenoceptors
Non-adrenergic idazoxan binding sites; Colocytes (Senard, J.M. (191) 59)

β-Adrenoceptors
Adenylate cyclase; Desensitisation; Myocytes; Noradrenaline (Jones, S.M. (191) 129)

Vas deferens (rat); Functional antagonism; Agonist dissociation constant; Efficacy (relative) (Diaz-Toledo, A. (191) 157)

α-Adrenoceptors (central)
Digastricus muscle (anterior); 5-HT receptors (central); (In vivo pharmacological test) (Rawlow, A. (191) 263)

Agonist dissociation constant
β-Adrenoceptors; Vas deferens (rat); Functional antagonism; Efficacy (relative) (Diaz-Toledo, A. (191) 157)

Aliphatic alcohols
NMDA receptors; Ethanol; Cerebral cortex (rat); Noradrenaline release (Fink, K. (191) 225)

Allergic conjunctivitis
Leukotriene D_4 receptor antagonists; MK-571; Leukotriene D_4; PAF (platelet activating factor, PAF-acether) (Chan, C.-C. (191) 273)

Aminoglycosides
Adenosine 3′,5′-cyclic monophosphate; [Arg^8]vasopressin (AVP); Collecting tubule; Henle's loop (thick ascending limb of) (Kidwell, D. (191) 489)

cAMP
Nitroprusside; Isoprenaline; cGMP; Smooth muscle; Aorta (rat) (Maurice, D.H. (191) 471)

Amphetamine
MDMA (3,4-methylenedioxymethamphetamine); Chloral hydrate (Schmidt, C.J. (191) 213)

Ascorbate; GBR-12909; Neostriatum; Quinpirole; SK&F 38393; Voltammetry (in vivo) (Pierce, R.C. (191) 295)

ANF (atrial natriuretic factor)
EDRF (release of); Endothelium-dependent relaxation; Nitric oxide (NO); Atherosclerosis (experimental); Hypercholesterolemia (Verbeuren, T.J. (191) 173)

Antiarrhythmic effect
Use-dependent block; Conduction velocity; Bunazosin; α_1-Adrenoceptor antagonists (Hasegawa, J. (191) 369)

0014-2999/90/$03.50 © 1990 Elsevier Science Publishers B.V. (Biomedical Division)

Antinociception
Opioids; U-50,488H; Formalin (Haley, J. (191) 437)

Aorta
Smooth muscle tone; Endothelin; Atriopeptin III; Methoxamine; (Rabbit) (Opgenorth, T.J. (191) 351)

Aorta (rat)
Nitroprusside; Isoprenaline; cGMP; cAMP; Smooth muscle (Maurice, D.H. (191) 471)

L-arginine
Gastric fundus (rat); N^G-Monomethyl-L-Arginine (L-NMMA); Nitric oxide; Non-adrenergic, non-cholinergic transmission; Vasoactive intestinal polypeptide (VIP) (Li, C.G. (191) 303)

L-Arginine pathway
Endotoxin; Smooth muscle (vascular); Ca^{2+} (Gray, G.A. (191) 89)

Arrhythmias
Reperfusion; Myocardial Na^{2+}; Myocardial K^+; Myocardial Ca^{2+}; Myocardial Mg^{2+}; Heart (rat) (Tosaki, A. (191) 69)

Ascorbate
Amphetamine; GBR-12909; Neostriatum; Quinpirole; SK&F 38393; Voltammetry (in vivo) (Pierce, R.C. (191) 295)

Atherosclerosis (experimental)
EDRF (release of); Endothelium-dependent relaxation; ANF (atrial natriuretic factor); Nitric oxide (NO); Hypercholesterolemia (Verbeuren, T.J. (191) 173)

Atriopeptin III
Smooth muscle tone; Endothelin; Methoxamine; Aorta; (Rabbit) (Opgenorth, T.J. (191) 351)

Autoradiography
CCK receptors; CCK (cholecystokinin); Brain (Carlberg, M. (191) 107)

BAM-12P
[Met^5]enkephalin; BAM-18P; BAM-22P; Peptide E (Davis, T.P. (191) 253)

BAM-18P
[Met^5]enkephalin; BAM-12P; BAM-22P; Peptide E (Davis, T.P. (191) 253)

BAM-22P
[Met^5]enkephalin; BAM-12P; BAM-18P; Peptide E (Davis, T.P. (191) 253)

Behavioral effects
Dopamine D_1 receptors; Dopamine D_2 receptors; Bombesin; SK&F 38393; Eticlopride; SCH 23390; PPHT (2-(N-phenethyl-N-propyl)amino-5-hydroxytetralin); Grooming behaviour; Locomotion (Merali, Z. (191) 281)

Behaviour
Nimodipine; Diltiazem; Phencyclidine; EEG (Popoli, P. (191) 141)

Inositol hexakisphosphate; Phosphatidylinositol cycle; Epilepsy; Excitotoxicity; EEG (Smith, S.E. (191) 337)

Blood flow
Substance P; Oedema; Nitric oxide (NO); Microvascular permeability (Hughes, S.R. (191) 481)

Bombesin
Dopamine D_1 receptors; Dopamine D_2 receptors; Behavioral effects; SK&F 38393; Eticlopride; SCH 23390; PPHT (2-(N-phenethyl-N-propyl)amino-5-hydroxytetralin); Grooming behaviour; Locomotion (Merali, Z. (191) 281)

Brain
CCK receptors; CCK (cholecystokinin); Autoradiography (Carlberg, M. (191) 107)

β-Endorphin; β-Endorphin metabolism; Neuroleptic drugs; (HPLC) (Konings, P.N.M. (191) 115)

Brain (mouse)
Dopamine D_1 receptors; Dopamine D_2 receptors; GABA synthesis (rate of); Gabaculine (Steulet, A.-F. (191) 19)

Brain slices (rat, superfused)
MDMA (3,4-methylenedioxymethamphetamine); Monoamine release; Noradrenaline; 5-HT (5-hydroxytryptamine, serotonin); Dopamine (Fitzgerald, J.L. (191) 217)

Bronchial artery
Ligustrazine; Pulmonary artery; Vasodilators; (Human) (Liu, S. (191) 345)

Bronchoconstriction
Endothelin; Heart; Lung; Endothelin receptors; Vasoconstriction (Hemsén, A. (191) 319)

Bunazosin
Use-dependent block; Conduction velocity; α_1-Adrenoceptor antagonists; Antiarrhythmic effect (Hasegawa, J. (191) 369)

Ca^{2+}
Endotoxin; Smooth muscle (vascular); L-Arginine pathway (Gray, G.A. (191) 89)

Cannula insertion method
Facial vein (simian); Acetylcholine; Muscarinic receptor subtypes; Vasoconstriction (Chiba, S. (191) 311)

CCK (cholecystokinin)
CCK receptors; Autoradiography; Brain (Carlberg, M. (191) 107)

CCK receptors
CCK (cholecystokinin); Autoradiography; Brain (Carlberg, M. (191) 107)

Cerebral artery (bovine)
Adrenoceptor function (heterogeneity of); Prazosin; Yohimbine; α_1-Adrenoceptors (Ayajiki, K. (191) 417)

Cerebral cortex (rat)
NMDA receptors; Ethanol; Aliphatic alcohols; Noradrenaline release (Fink, K. (191) 225)

CGRP (calcitonin gene-related peptide)
Norepinephrine release; Medulla oblongata; Spontaneously hypertensive rats (SHR); Wistar-Kyoto rats (WKY) (Tsuda, K. (191) 101)

Chloral hydrate
Amphetamine; MDMA (3,4-methylenedioxymethamphetamine) (Schmidt, C.J. (191) 213)

p-Chloroamphetamine
1-(4-Chlorophenyl)-2-aminobutane (CAB); Drug discrimination; Microdialysis in vivo; Uptake inhibition; 5-HT neurotoxicity (Johnson, M.P. (191) 1)

7-Chlorokynurenic acid
NMDA (N-methyl-D-aspartate); HA-966; Glycine; Spinal cord; Cortical wedge; (Electrophysiology) (Brugger, F. (191) 29)

1-(4-Chlorophenyl)-2-aminobutane (CAB)
p-Chloroamphetamine; Drug discrimination; Microdialysis in vivo; Uptake inhibition; 5-HT neurotoxicity (Johnson, M.P. (191) 1)

Cholecystokinin (CCK)
Insulin secretion; Glucagon secretion; Peptide receptor antagonists; Vasoactive intestinal polypeptide (VIP); Gastrin-releasing peptide (GRP); (Mouse); (In vivo) (Karlsson, S. (191) 457)

Ciliary muscle
EGF (epidermal growth factor-urogastrone); Prostaglandin E_1; Vasopressin (Yamaguchi, K. (191) 245)

Clozapine
[^{3}H]Mesulergine; [^{3}H]Ketanserin; 5-HT_{1C} receptors; 5-HT_2 receptors (Canton, H. (191) 93)

Collecting tubule
Aminoglycosides; Adenosine 3′,5′-cyclic monophosphate; [Arg^8]vasopressin (AVP); Henle's loop (thick ascending limb of) (Kidwell, D. (191) 489)

Colocytes
α_2-Adrenoceptors; Non-adrenergic idazoxan binding sites (Senard, J.M. (191) 59)

Colon (rat)
Sennosides; Rhein; Rheinanthrone; Histamine (Autore, G. (191) 97)

Conduction velocity
Use-dependent block; Bunazosin; α_1-Adrenoceptor antagonists; Antiarrhythmic effect (Hasegawa, J. (191) 369)

Convulsions
Pilocarpine; Striatum; Dopamine D_1 receptors (Al-Tajir, G. (191) 329)

Coronary artery
Prostaglandin $F_{2\alpha}$-induced contractions; Thromboxane receptor antagonists; Smooth muscle (vascular) (Nakajima, M. (191) 359)

Cortical wedge
NMDA (N-methyl-D-aspartate); 7-Chlorokynurenic acid; HA-966; Glycine; Spinal cord; (Electrophysiology) (Brugger, F. (191) 29)

Desensitisation
Adenylate cyclase; β-Adrenoceptors; Myocytes; Noradrenaline (Jones, S.M. (191) 129)

Digastricus muscle (anterior)
5-HT receptors (central); α-Adrenoceptors (central); (In vivo pharmacological test) (Rawlow, A. (191) 263)

Diltiazem
Nimodipine; Phencyclidine; EEG; Behaviour (Popoli, P. (191) 141)

DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane)
5-HT (5-hydroxytryptamine, serotonin); 5-HT receptors; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin; ICI 169,369; Ritanserin; TFMPP (1-[3-(trifluoromethyl)phenyl]-piperazine); Tail flicks (spontaneous); (Rat) (Bervoets, K. (191) 185)

Domperidone
Dopamine; Hyperpolarization; Salivary gland; (Cockroach) (Evans, A.M. (191) 465)

DOPAC (3,4-dihydroxyphenylacetic acid)
Haloperidol (chronic); Dopamine; Striatum; (Endogenous release); (Ex vivo study) (Umeda, Y. (191) 149)

Dopamine
Haloperidol (chronic); DOPAC (3,4-dihydroxyphenylacetic acid); Striatum; (Endogenous release); (Ex vivo study) (Umeda, Y. (191) 149)

MDMA (3,4-methylenedioxymethamphetamine); Monoamine release; Brain slices (rat, superfused); Noradrenaline; 5-HT (5-hydroxytryptamine, serotonin) (Fitzgerald, J.L. (191) 217)

Domperidone; Hyperpolarization; Salivary gland; (Cockroach) (Evans, A.M. (191) 465)

Dopamine receptors
5-HT_{1A} receptors; Locomotion; α-Adrenoceptor antagonists; β-Adrenoceptor antagonists (Kalkman, H.O. (191) 383)

Dopamine D_1 receptors
Dopamine D_2 receptors; GABA synthesis (rate of); Gabaculine; Brain (mouse) (Steulet, A.-F. (191) 19)

Dopamine D_2 receptors; Behavioral effects; Bombesin; SK&F 38393; Eticlopride; SCH 23390; PPHT (2-(N-phenethyl-N-propyl)amino-5-hydroxytetralin); Grooming behaviour; Locomotion (Merali, Z. (191) 281)

Pilocarpine; Convulsions; Striatum (Al-Tajir, G. (191) 329)

Dopamine D_2 receptors
Dopamine D_1 receptors; GABA synthesis (rate of); Gabaculine; Brain (mouse) (Steulet, A.-F. (191) 19)

Dopamine D_1 receptors; Behavioral effects; Bombesin; SK&F 38393; Eticlopride; SCH 23390; PPHT (2-(N-phenethyl-N-propyl)amino-5-hydroxytetralin); Grooming behaviour; Locomotion (Merali, Z. (191) 281)

Drug discrimination
p-Chloroamphetamine; 1-(4-Chlorophenyl)-2-aminobutane (CAB); Microdialysis in vivo; Uptake inhibition; 5-HT neurotoxicity (Johnson, M.P. (191) 1)

EDRF (release of)
Endothelium-dependent relaxation; ANF (atrial natriuretic factor); Nitric oxide (NO); Atherosclerosis (experimental); Hypercholesterolemia (Verbeuren, T.J. (191) 173)

EEG
Nimodipine; Diltiazem; Phencyclidine; Behaviour (Popoli, P. (191) 141)

Inositol hexakisphosphate; Phosphatidylinositol cycle; Epilepsy; Behaviour; Excitotoxicity (Smith, S.E. (191) 337)

Efficacy (relative)
β-Adrenoceptors; Vas deferens (rat); Functional antagonism; Agonist dissociation constant (Diaz-Toledo, A. (191) 157)

EGF (epidermal growth factor-urogastrone)
Ciliary muscle; Prostaglandin E_1; Vasopressin (Yamaguchi, K. (191) 245)

Elevated plus-maze
Infantile stimulation; Ro 15-1788 (perinatal); Exploration; (Rat) (Fernández-Teruel, A. (191) 111)

β-Endorphin
β-Endorphin metabolism; Neuroleptic drugs; Brain; (HPLC) (Konings, P.N.M. (191) 115)

β-Endorphin metabolism
β-Endorphin; Neuroleptic drugs; Brain; (HPLC) (Konings, P.N.M. (191) 115)

Endothelin
Bronchoconstriction; Heart; Lung; Endothelin receptors; Vasoconstriction (Hemsén, A. (191) 319)

Smooth muscle tone; Atriopeptin III; Methoxamine; Aorta; (Rabbit) (Opgenorth, T.J. (191) 351)

Endothelin receptors
Bronchoconstriction; Endothelin; Heart; Lung; Vasoconstriction (Hemsén, A. (191) 319)

Endothelium-dependent relaxation
EDRF (release of); ANF (atrial natriuretic factor); Nitric oxide (NO); Atherosclerosis (experimental); Hypercholesterolemia (Verbeuren, T.J. (191) 173)

Endotoxin
Smooth muscle (vascular); Ca^{2+}; L-Arginine pathway (Gray, G.A. (191) 89)

Nitric oxide (NO); Vascular injury; Nitro-vasodilators; N^G-Monomethyl-L-arginine (L-NMMA) (Boughton-Smith, N.K. (191) 485)

[Met^5]enkephalin
BAM-12P; BAM-18P; BAM-22P; Peptide E (Davis, T.P. (191) 253)

Epilepsy
Inositol hexakisphosphate; Phosphatidylinositol cycle; Behaviour; Excitotoxicity; EEG (Smith, S.E. (191) 337)

Ethanol
NMDA receptors; Aliphatic alcohols; Cerebral cortex (rat); Noradrenaline release (Fink, K. (191) 225)

Ethanol lesions
Propranolol; Timolol; Indomethacin; Prostaglandin release; Membrane stabilising action (Bhandare, P. (191) 167)

Eticlopride
Dopamine D_1 receptors; Dopamine D_2 receptors; Behavioral effects; Bombesin; SK&F 38393; SCH 23390; PPHT (2-(N-phenethyl-N-propyl)amino-5-hydroxytetralin); Grooming behaviour; Locomotion (Merali, Z. (191) 281)

Excitotoxicity
Inositol hexakisphosphate; Phosphatidylinositol cycle; Epilepsy; Behaviour; EEG (Smith, S.E. (191) 337)

Exploration
Infantile stimulation; Ro 15-1788 (perinatal); Elevated plus-maze; (Rat) (Fernández-Teruel, A. (191) 111)

Facial vein (simian)
Cannula insertion method; Acetylcholine; Muscarinic receptor subtypes; Vasoconstriction (Chiba, S. (191) 311)

Flexor reflex
Opioids; Spinal cord; Spinal cord injury (Hao, J. (191) 407)

Formalin
Opioids; U-50,488H; Antinociception (Haley, J. (191) 437)

Forskolin
Smooth muscle (cerebrovascular); Second messengers; Phorbol 12,13-dibutyrate; Pial vessels; (In vitro pharmacology) (Horsburgh, K. (191) 205)

Functional antagonism
β-Adrenoceptors; Vas deferens (rat); Agonist dissociation constant; Efficacy (relative) (Diaz-Toledo, A. (191) 157)

Gabaculine
Dopamine D_1 receptors; Dopamine D_2 receptors; GABA synthesis (rate of); Brain (mouse) (Steulet, A.-F. (191) 19)

GABA synthesis (rate of)
Dopamine D_1 receptors; Dopamine D_2 receptors; Gabaculine; Brain (mouse) (Steulet, A.-F. (191) 19)

Galanin
Somatostatin release; Rin-m cells; G-proteins (guanine nucleotide-binding proteins) (Amiranoff, B. (191) 401)

Gastric emptying
5-HT_3 receptors; Protein meals; Ondansetron (Forster, E.R. (191) 235)

Gastric fundus (rat)
N^G-Monomethyl-L-Arginine (L-NMMA); L-arginine; Nitric oxide; Non-adrenergic, non-cholinergic transmission; Vasoactive intestinal polypeptide (VIP) (Li, C.G. (191) 303)

Gastrin-releasing peptide (GRP)
Insulin secretion; Glucagon secretion; Peptide receptor antagonists; Vasoactive intestinal polypeptide (VIP); Cholecystokinin (CCK); (Mouse); (In vivo) (Karlsson, S. (191) 457)

GBR-12909
Amphetamine; Ascorbate; Neostriatum; Quinpirole; SK&F 38393; Voltammetry (in vivo) (Pierce, R.C. (191) 295)

Glucagon secretion
Insulin secretion; Peptide receptor antagonists; Vasoactive intestinal polypeptide (VIP); Gastrin-releasing peptide (GRP); Cholecystokinin (CCK); (Mouse); (In vivo) (Karlsson, S. (191) 457)

Glyburide
RP 52891; 5-Hydroxydecanoate, sodium; Myocardial ischemia; K^+ channel activators (Grover, G.J. (191) 11)

Glycine
NMDA (N-methyl-D-aspartate); 7-Chlorokynurenic acid; HA-966; Spinal cord; Cortical wedge; (Electrophysiology) (Brugger, F. (191) 29)

NMDA (N-methyl-D-aspartate); Noradrenaline release; Hippocampus (rat); Synaptosomes (superfused) (Pittaluga, A. (191) 231)

Glycine/NMDA receptors
κ-Opioid receptors; NMDLA (N-methyl-DL-aspartate); NMDLA infusion; Seizures (Singh, L. (191) 477)

cGMP
Nitroprusside; Isoprenaline; cAMP; Smooth muscle; Aorta (rat) (Maurice, D.H. (191) 471)

G-proteins (guanine nucleotide-binding proteins)
Milrinone; Pertussis toxin (Verrijk, R. (191) 197)

Galanin; Somatostatin release; Rin-m cells (Amiranoff, B. (191) 401)

Grooming behaviour
Dopamine D_1 receptors; Dopamine D_2 receptors; Behavioral effects; Bombesin; SK&F 38393; Eticlopride; SCH 23390; PPHT (2-(N-phenethyl-N-propyl)amino-5-hydroxytetralin); Locomotion (Merali, Z. (191) 281)

HA-966
NMDA (N-methyl-D-aspartate); 7-Chlorokynurenic acid; Glycine; Spinal cord; Cortical wedge; (Electrophysiology) (Brugger, F. (191) 29)

Haloperidol (chronic)
Dopamine; DOPAC (3,4-dihydroxyphenylacetic acid); Striatum; (Endogenous release); (Ex vivo study) (Umeda, Y. (191) 149)

Heart
Bronchoconstriction; Endothelin; Lung; Endothelin receptors; Vasoconstriction (Hemsén, A. (191) 319)

Heart (rat)
Reperfusion; Arrhythmias; Myocardial Na^{2+}; Myocardial K^+; Myocardial Ca^{2+}; Myocardial Mg^{2+} (Tosaki, A. (191) 69)

Henle's loop (thick ascending limb of)
Aminoglycosides; Adenosine 3′,5′-cyclic monophosphate; [Arg^8]vasopressin (AVP); Collecting tubule (Kidwell, D. (191) 489)

Hippocampus (rat)
NMDA (N-methyl-D-aspartate); Noradrenaline release; Synaptosomes (superfused); Glycine (Pittaluga, A. (191) 231)

Histamine
Sennosides; Rhein; Rheinanthrone; Colon (rat) (Autore, G. (191) 97)

5-HT (5-hydroxytryptamine, serotonin)
5-HT receptors; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin; ICI 169,369; Ritanserin; TFMPP (1-[3-(trifluoromethyl)phenyl]piperazine); Tail flicks (spontaneous); DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); (Rat) (Bervoets, K. (191) 185)

MDMA (3,4-methylenedioxymethamphetamine); Monoamine release; Brain slices (rat, superfused); Noradrenaline; Dopamine (Fitzgerald, J.L. (191) 217)

5-HT receptors; Ketanserin; Methiothepin; Saphenous vein; (Rabbit) (Van Heuven-Nolsen, D. (191) 375)

5-HT neurotoxicity
p-Chloroamphetamine; 1-(4-Chlorophenyl)-2-aminobutane (CAB); Drug discrimination; Microdialysis in vivo; Uptake inhibition (Johnson, M.P. (191) 1)

5-HT receptors
5-HT (5-hydroxytryptamine, serotonin); 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin; ICI 169,369; Ritanserin; TFMPP (1-[3-(trifluoromethyl)phenyl]piperazine); Tail flicks (spontaneous); DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); (Rat) (Bervoets, K. (191) 185)

5-HT (5-hydroxytryptamine, serotonin); Ketanserin; Methiothepin; Saphenous vein; (Rabbit) (Van Heuven-Nolsen, D. (191) 375)

5-HT_{1A} receptors
Locomotion; α-Adrenoceptor antagonists; β-Adrenoceptor antagonists; Dopamine receptors (Kalkman, H.O. (191) 383)

MDL 73005EF (8-[2-(2,3-dihydro-1,4-benzodioxin-2-yl)methylamino]-8-azaspiro[4,5]decan-7,9-dione methyl sulphonate); 5-HT release; ACTH (adrenocorticotropin); Microdialysis (brain, in vivo); Radioimmunoassay (Gartside, S.E. (191) 391)

5-HT_{1C} receptors
[^{3}H]Mesulergine; [^{3}H]Ketanserin; 5-HT_2 receptors; Clozapine (Canton, H. (191) 93)

5-HT_2 receptors
[^{3}H]Mesulergine; [^{3}H]Ketanserin; 5-HT_{1C} receptors; Clozapine (Canton, H. (191) 93)

5-HT_3 receptors
Gastric emptying; Protein meals; Ondansetron (Forster, E.R. (191) 235)

5-HT receptors (central)
Digastricus muscle (anterior); α-Adrenoceptors (central); (In vivo pharmacological test) (Rawlow, A. (191) 263)

5-HT release
MDL 73005EF (8-[2-(2,3-dihydro-1,4-benzodioxin-2-yl)methylamino]-8-azaspiro[4,5]decan-7,9-dione methyl sulphonate); 5-HT_{1A} receptors; ACTH (adrenocorticotropin); Microdialysis (brain, in vivo); Radioimmunoassay (Gartside, S.E. (191) 391)

5-Hydroxydecanoate, sodium
RP 52891; Glyburide; Myocardial ischemia; K^+ channel activators (Grover, G.J. (191) 11)

Hypercholesterolemia
EDRF (release of); Endothelium-dependent relaxation; ANF (atrial natriuretic factor); Nitric oxide (NO); Atherosclerosis (experimental) (Verbeuren, T.J. (191) 173)

Hyperpolarization
Domperidone; Dopamine; Salivary gland; (Cockroach) (Evans, A.M. (191) 465)

ICI 169,369
5-HT (5-hydroxytryptamine, serotonin); 5-HT receptors; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin; Ritanserin; TFMPP (1-[3-(trifluoromethyl)phenyl]piperazine); Tail flicks (spontaneous); DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); (Rat) (Bervoets, K. (191) 185)

Indobufen
Thromboxane B_2; Leukotriene B_4; Prostaglandin E_2; Platelet cyclooxygenase (Patrignani, P. (191) 83)

Indomethacin
Propranolol; Ethanol lesions; Timolol; Prostaglandin release; Membrane stabilising action (Bhandare, P. (191) 167)

Infantile stimulation
Ro 15-1788 (perinatal); Elevated plus-maze; Exploration; (Rat) (Fernández-Teruel, A. (191) 111)

Inositol hexakisphosphate
Phosphatidylinositol cycle; Epilepsy; Behaviour; Excitotoxicity; EEG (Smith, S.E. (191) 337)

Insulin secretion
Glucagon secretion; Peptide receptor antagonists; Vasoactive intestinal polypeptide (VIP); Gastrin-releasing peptide (GRP); Cholecystokinin (CCK); (Mouse); (In vivo) (Karlsson, S. (191) 457)

Isoprenaline
Nitroprusside; cGMP; cAMP; Smooth muscle; Aorta (rat) (Maurice, D.H. (191) 471)

K^+ channel activators
RP 52891; Glyburide; 5-Hydroxydecanoate, sodium; Myocardial ischemia (Grover, G.J. (191) 11)

Ketanserin
5-HT (5-hydroxytryptamine, serotonin); 5-HT receptors; Methiothepin; Saphenous vein; (Rabbit) (Van Heuven-Nolsen, D. (191) 375)

[^{3}H]Ketanserin
[^{3}H]Mesulergine; 5-HT_{1C} receptors; 5-HT_2 receptors; Clozapine (Canton, H. (191) 93)

Leukotriene B_4
Thromboxane B_2; Prostaglandin E_2; Indobufen; Platelet cyclooxygenase (Patrignani, P. (191) 83)

Leukotriene D_4
Allergic conjunctivitis; Leukotriene D_4 receptor antagonists; MK-571; PAF (platelet activating factor, PAF-acether) (Chan, C.-C. (191) 273)

Leukotriene D_4 receptor antagonists
Allergic conjunctivitis; MK-571; Leukotriene D_4; PAF (platelet activating factor, PAF-acether) (Chan, C.-C. (191) 273)

Ligustrazine
Pulmonary artery; Bronchial artery; Vasodilators; (Human) (Liu, S. (191) 345)

Locomotion
Dopamine D_1 receptors; Dopamine D_2 receptors; Behavioral effects; Bombesin; SK&F 38393; Eticlopride; SCH 23390; PPHT (2-(N-phenethyl-N-propyl)amino-5-hydroxytetralin); Grooming behaviour (Merali, Z. (191) 281)

5-HT_{1A} receptors; α-Adrenoceptor antagonists; β-Adrenoceptor antagonists; Dopamine receptors (Kalkman, H.O. (191) 383)

Lung
Bronchoconstriction; Endothelin; Heart; Endothelin receptors; Vasoconstriction (Hemsén, A. (191) 319)

Lung lobe perfusion (isolated)
Pulmonary vasoconstriction (hypoxic); Pindolol; Propranolol (Takashio, T. (191) 493)

MDL 73005EF (8-[2-(2,3-dihydro-1,4-benzodioxin-2-yl)methylamino]-8-azaspiro[4,5]decan-7,9-dione methyl sulphonate)
5-HT_{1A} receptors; 5-HT release; ACTH (adrenocorticotropin); Microdialysis (brain, in vivo); Radioimmunoassay (Gartside, S.E. (191) 391)

MDMA (3,4-methylenedioxymethamphetamine)
Amphetamine; Chloral hydrate (Schmidt, C.J. (191) 213)

Monoamine release; Brain slices (rat, superfused); Noradrenaline; 5-HT (5-hydroxytryptamine, serotonin); Dopamine (Fitzgerald, J.L. (191) 217)

Medulla oblongata
CGRP (calcitonin gene-related peptide); Norepinephrine release; Spontaneously hypertensive rats (SHR); Wistar-Kyoto rats (WKY) (Tsuda, K. (191) 101)

Membrane stabilising action
Propranolol; Ethanol lesions; Timolol; Indomethacin; Prostaglandin release (Bhandare, P. (191) 167)

[^{3}H]Mesulergine
[^{3}H]Ketanserin; 5-HT_{1C} receptors; 5-HT_2 receptors; Clozapine (Canton, H. (191) 93)

Methiothepin
5-HT (5-hydroxytryptamine, serotonin); 5-HT receptors; Ketanserin; Saphenous vein; (Rabbit) (Van Heuven-Nolsen, D. (191) 375)

Methoxamine
Smooth muscle tone; Endothelin; Atriopeptin III; Aorta; (Rabbit) (Opgenorth, T.J. (191) 351)

Adenylate cyclase-cyclic AMP system; Vasorelaxation; Precontraction levels; (Canine veins) (Tsuru, H. (191) 447)

Microdialysis (brain, in vivo)
MDL 73005EF (8-[2-(2,3-dihydro-1,4-benzodioxin-2-yl)methylamino]-8-azaspiro[4,5]decan-7,9-dione methyl sulphonate); 5-HT_{1A} receptors; 5-HT release; ACTH (adrenocorticotropin); Radioimmunoassay (Gartside, S.E. (191) 391)

Microdialysis in vivo
p-Chloroamphetamine; 1-(4-Chlorophenyl)-2-aminobutane (CAB); Drug discrimination; Uptake inhibition; 5-HT neurotoxicity (Johnson, M.P. (191) 1)

Microvascular permeability
Substance P; Oedema; Nitric oxide (NO); Blood flow (Hughes, S.R. (191) 481)

Milrinone
G-proteins (guanine nucleotide-binding proteins); Pertussis toxin (Verrijk, R. (191) 197)

MK-571
Allergic conjunctivitis; Leukotriene D_4 receptor antagonists; Leukotriene D_4; PAF (platelet activating factor, PAF-acether) (Chan, C.-C. (191) 273)

Monoamine release
MDMA (3,4-methylenedioxymethamphetamine); Brain slices (rat, superfused); Noradrenaline; 5-HT (5-hydroxytryptamine, serotonin); Dopamine (Fitzgerald, J.L. (191) 217)

N^G-Monomethyl-L-Arginine (L-NMMA)
Gastric fundus (rat); L-arginine; Nitric oxide; Non-adrenergic, non-cholinergic transmission; Vasoactive intestinal polypeptide (VIP) (Li, C.G. (191) 303)

Endotoxin; Nitric oxide (NO); Vascular injury; Nitro-vasodilators (Boughton-Smith, N.K. (191) 485)

Muscarinic receptors
Receptor classification; Schild analysis; Receptor coupling (Kenakin, T.P. (191) 39)

Receptor classification; Schild analysis; Pirenzepine; (Resultant analysis) (Boselli, C. (191) 49)

Muscarinic receptor subtypes
Facial vein (simian); Cannula insertion method; Acetylcholine; Vasoconstriction (Chiba, S. (191) 311)

Myocardial Ca^{2+}
Reperfusion; Arrhythmias; Myocardial Na^{2+}; Myocardial K^+; Myocardial Mg^{2+}; Heart (rat) (Tosaki, A. (191) 69)

Myocardial ischemia
RP 52891; Glyburide; 5-Hydroxydecanoate, sodium; K^+ channel activators (Grover, G.J. (191) 11)

Myocardial K^+
Reperfusion; Arrhythmias; Myocardial Na^{2+}; Myocardial Ca^{2+}; Myocardial Mg^{2+}; Heart (rat) (Tosaki, A. (191) 69)

Myocardial Mg^{2+}
Reperfusion; Arrhythmias; Myocardial Na^{2+}; Myocardial K^+; Myocardial Ca^{2+}; Heart (rat) (Tosaki, A. (191) 69)

Myocardial Na^{2+}
Reperfusion; Arrhythmias; Myocardial K^+; Myocardial Ca^{2+}; Myocardial Mg^{2+}; Heart (rat) (Tosaki, A. (191) 69)

Myocytes
Adenylate cyclase; β-Adrenoceptors; Desensitisation; Noradrenaline (Jones, S.M. (191) 129)

Neostriatum
Amphetamine; Ascorbate; GBR-12909; Quinpirole; SK&F 38393; Voltammetry (in vivo) (Pierce, R.C. (191) 295)

Neuroleptic drugs
β-Endorphin; β-Endorphin metabolism; Brain; (HPLC) (Konings, P.N.M. (191) 115)

Nimodipine
Diltiazem; Phencyclidine; EEG; Behaviour (Popoli, P. (191) 141)

[^{3}H]Nisoxetine
Norepinephrine; Uptake sites (Tejani-Butt, S.M. (191) 239)

Nitric oxide
Gastric fundus (rat); N^G-Monomethyl-L-Arginine (L-NMMA); L-arginine; Non-adrenergic, non-cholinergic transmission; Vasoactive intestinal polypeptide (VIP) (Li, C.G. (191) 303)

Nitric oxide (NO)
EDRF (release of); Endothelium-dependent relaxation; ANF (atrial natriuretic factor); Atherosclerosis (experimental); Hypercholesterolemia (Verbeuren, T.J. (191) 173)

Substance P; Oedema; Blood flow; Microvascular permeability (Hughes, S.R. (191) 481)

Endotoxin; Vascular injury; Nitro-vasodilators; N^G-Monomethyl-L-arginine (L-NMMA) (Boughton-Smith, N.K. (191) 485)

Nitroprusside
Isoprenaline; cGMP; cAMP; Smooth muscle; Aorta (rat) (Maurice, D.H. (191) 471)

Nitro-vasodilators
Endotoxin; Nitric oxide (NO); Vascular injury; N^G-Monomethyl-L-arginine (L-NMMA) (Boughton-Smith, N.K. (191) 485)

NMDA (N-methyl-D-aspartate)
7-Chlorokynurenic acid; HA-966; Glycine; Spinal cord; Cortical wedge; (Electrophysiology) (Brugger, F. (191) 29)

Noradrenaline release; Hippocampus (rat); Synaptosomes (superfused); Glycine (Pittaluga, A. (191) 231)

NMDA receptors
Ethanol; Aliphatic alcohols; Cerebral cortex (rat); Noradrenaline release (Fink, K. (191) 225)

NMDLA infusion
κ-Opioid receptors; Glycine/NMDA receptors; NMDLA (N-methyl-DL-aspartate); Seizures (Singh, L. (191) 477)

NMDLA (N-methyl-DL-aspartate)
κ-Opioid receptors; Glycine/NMDA receptors; NMDLA infusion; Seizures (Singh, L. (191) 477)

Non-adrenergic idazoxan binding sites
α_2-Adrenoceptors; Colocytes (Senard, J.M. (191) 59)

Non-adrenergic, non-cholinergic transmission
Gastric fundus (rat); N^G-Monomethyl-L-Arginine (L-NMMA); L-arginine; Nitric oxide; Vasoactive intestinal polypeptide (VIP) (Li, C.G. (191) 303)

Noradrenaline
Adenylate cyclase; β-Adrenoceptors; Desensitisation; Myocytes (Jones, S.M. (191) 129)

MDMA (3,4-methylenedioxymethamphetamine); Monoamine release; Brain slices (rat, superfused); 5-HT (5-hydroxytryptamine, serotonin); Dopamine (Fitzgerald, J.L. (191) 217)

Noradrenaline release
NMDA receptors; Ethanol; Aliphatic alcohols; Cerebral cortex (rat) (Fink, K. (191) 225)

NMDA (N-methyl-D-aspartate); Hippocampus (rat); Synaptosomes (superfused); Glycine (Pittaluga, A. (191) 231)

Norepinephrine
Uptake sites; [^{3}H]Nisoxetine (Tejani-Butt, S.M. (191) 239)

Norepinephrine release
CGRP (calcitonin gene-related peptide); Medulla oblongata; Spontaneously hypertensive rats (SHR); Wistar-Kyoto rats (WKY) (Tsuda, K. (191) 101)

Octopamine receptors
Adrenoceptors; (Insect); (Locust) (Roeder, T. (191) 221)

Oedema
Substance P; Nitric oxide (NO); Blood flow; Microvascular permeability (Hughes, S.R. (191) 481)

8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin
5-HT (5-hydroxytryptamine, serotonin); 5-HT receptors; ICI 169,369; Ritanserin; TFMPP (1-[3-(trifluoromethyl)phenyl]-piperazine); Tail flicks (spontaneous); DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); (Rat) (Bervoets, K. (191) 185)

Ondansetron
Gastric emptying; 5-HT$_3$ receptors; Protein meals (Forster, E.R. (191) 235)

κ-Opioid receptors
Glycine/NMDA receptors; NMDLA (N-methyl-DL-aspartate); NMDLA infusion; Seizures (Singh, L. (191) 477)

Opioids
Spinal cord; Flexor reflex; Spinal cord injury (Hao, J. (191) 407)

U-50,488H; Formalin; Antinociception (Haley, J. (191) 437)

Oxytocin analogues (radiolabelled)
Uterus (human); Oxytocin receptors; Vasopressin receptors; Vasopressin analogues (radiolabelled); Pregnancy (Tence, M. (191) 427)

Oxytocin receptors
Uterus (human); Vasopressin receptors; Vasopressin analogues (radiolabelled); Oxytocin analogues (radiolabelled); Pregnancy (Tence, M. (191) 427)

PAF (platelet activating factor, PAF-acether)
Allergic conjunctivitis; Leukotriene D$_4$ receptor antagonists; MK-571; Leukotriene D$_4$ (Chan, C.-C. (191) 273)

Peptide E
[Met^5]enkephalin; BAM-12P; BAM-18P; BAM-22P (Davis, T.P. (191) 253)

Peptide receptor antagonists
Insulin secretion; Glucagon secretion; Vasoactive intestinal polypeptide (VIP); Gastrin-releasing peptide (GRP); Cholecystokinin (CCK); (Mouse); (In vivo) (Karlsson, S. (191) 457)

Pertussis toxin
Milrinone; G-proteins (guanine nucleotide-binding proteins) (Verrijk, R. (191) 197)

Phencyclidine
Nimodipine; Diltiazem; EEG; Behaviour (Popoli, P. (191) 141)

Phorbol 12,13-dibutyrate
Smooth muscle (cerebrovascular); Second messengers; Forskolin; Pial vessels; (In vitro pharmacology) (Horsburgh, K. (191) 205)

Phosphatidylinositol cycle
Inositol hexakisphosphate; Epilepsy; Behaviour; Excitotoxicity; EEG (Smith, S.E. (191) 337)

Pial vessels
Smooth muscle (cerebrovascular); Second messengers; Forskolin; Phorbol 12,13-dibutyrate; (In vitro pharmacology) (Horsburgh, K. (191) 205)

Pilocarpine
Convulsions; Striatum; Dopamine D$_1$ receptors (Al-Tajir, G. (191) 329)

Pindolol
Pulmonary vasoconstriction (hypoxic); Propranolol; Lung lobe perfusion (isolated) (Takashio, T. (191) 493)

Pirenzepine
Muscarinic receptors; Receptor classification; Schild analysis; (Resultant analysis) (Boselli, C. (191) 49)

Platelet cyclooxygenase
Thromboxane B$_2$; Leukotriene B$_4$; Prostaglandin E$_2$; Indobufen (Patrignani, P. (191) 83)

PPHT (2-(N-phenethyl-N-propyl)amino-5-hydroxytetralin)
Dopamine D$_1$ receptors; Dopamine D$_2$ receptors; Behavioral effects; Bombesin; SK&F 38393; Eticlopride; SCH 23390; Grooming behaviour; Locomotion (Merali, Z. (191) 281)

Prazosin
Cerebral artery (bovine); Adrenoceptor function (heterogeneity of); Yohimbine; α$_1$-Adrenoceptors (Ayajiki, K. (191) 417)

Precontraction levels
Adenylate cyclase-cyclic AMP system; Vasorelaxation; Methoxamine; (Canine veins) (Tsuru, H. (191) 447)

Pregnancy
Uterus (human); Oxytocin receptors; Vasopressin receptors; Vasopressin analogues (radiolabelled); Oxytocin analogues (radiolabelled) (Tence, M. (191) 427)

Propranolol
Ethanol lesions; Timolol; Indomethacin; Prostaglandin release; Membrane stabilising action (Bhandare, P. (191) 167)

Pulmonary vasoconstriction (hypoxic); Pindolol; Lung lobe perfusion (isolated) (Takashio, T. (191) 493)

Prostaglandin E_1
EGF (epidermal growth factor-urogastrone); Ciliary muscle; Vasopressin (Yamaguchi, K. (191) 245)

Prostaglandin E_2
Thromboxane B_2; Leukotriene B_4; Indobufen; Platelet cyclooxygenase (Patrignani, P. (191) 83)

Prostaglandin $F_{2\alpha}$-induced contractions
Thromboxane receptor antagonists; Smooth muscle (vascular); Coronary artery (Nakajima, M. (191) 359)

Prostaglandin release
Propranolol; Ethanol lesions; Timolol; Indomethacin; Membrane stabilising action (Bhandare, P. (191) 167)

Protein meals
Gastric emptying; 5-HT_3 receptors; Ondansetron (Forster, E.R. (191) 235)

Pulmonary artery
Ligustrazine; Bronchial artery; Vasodilators; (Human) (Liu, S. (191) 345)

Pulmonary vasoconstriction (hypoxic)
Pindolol; Propranolol; Lung lobe perfusion (isolated) (Takashio, T. (191) 493)

Quinpirole
Amphetamine; Ascorbate; GBR-12909; Neostriatum; SK&F 38393; Voltammetry (in vivo) (Pierce, R.C. (191) 295)

Radioimmunoassay
MDL 73005EF (8-[2-(2,3-dihydro-1,4-benzodioxin-2-yl)methylamino]-8-azaspiro[4,5]decan-7,9-dione methyl sulphonate); 5-HT_{1A} receptors; 5-HT release; ACTH (adrenocorticotropin); Microdialysis (brain, in vivo) (Gartside, S.E. (191) 391)

Receptor classification
Muscarinic receptors; Schild analysis; Receptor coupling (Kenakin, T.P. (191) 39)

Muscarinic receptors; Schild analysis; Pirenzepine; (Resultant analysis) (Boselli, C. (191) 49)

Receptor coupling
Muscarinic receptors; Receptor classification; Schild analysis (Kenakin, T.P. (191) 39)

Reperfusion
Arrhythmias; Myocardial Na^{2+}; Myocardial K^+; Myocardial Ca^{2+}; Myocardial Mg^{2+}; Heart (rat) (Tosaki, A. (191) 69)

Rhein
Sennosides; Rheinanthrone; Histamine; Colon (rat) (Autore, G. (191) 97)

Rheinanthrone
Sennosides; Rhein; Histamine; Colon (rat) (Autore, G. (191) 97)

Rin-m cells
Galanin; Somatostatin release; G-proteins (guanine nucleotide-binding proteins) (Amiranoff, B. (191) 401)

Ritanserin
5-HT (5-hydroxytryptamine, serotonin); 5-HT receptors; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin; ICI 169,369; TFMPP (1-[3-(trifluoromethyl)phenyl]piperazine); Tail flicks (spontaneous); DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); (Rat) (Bervoets, K. (191) 185)

Ro 15-1788 (perinatal)
Infantile stimulation; Elevated plus-maze; Exploration; (Rat) (Fernández-Teruel, A. (191) 111)

RP 52891
Glyburide; 5-Hydroxydecanoate, sodium; Myocardial ischemia; K^+ channel activators (Grover, G.J. (191) 11)

Salivary gland
Domperidone; Dopamine; Hyperpolarization; (Cockroach) (Evans, A.M. (191) 465)

Saphenous vein
5-HT (5-hydroxytryptamine, serotonin); 5-HT receptors; Ketanserin; Methiothepin; (Rabbit) (Van Heuven-Nolsen, D. (191) 375)

SCH 23390
Dopamine D_1 receptors; Dopamine D_2 receptors; Behavioral effects; Bombesin; SK&F 38393; Eticlopride;. PPHT (2-(N-phenethyl-N-propyl)amino-5-hydroxytetralin); Grooming behaviour; Locomotion (Merali, Z. (191) 281)

Schild analysis
Muscarinic receptors; Receptor classification; Receptor coupling (Kenakin, T.P. (191) 39)

Muscarinic receptors; Receptor classification; Pirenzepine; (Resultant analysis) (Boselli, C. (191) 49)

Second messengers
Smooth muscle (cerebrovascular); Forskolin; Phorbol 12,13-dibutyrate; Pial vessels; (In vitro pharmacology) (Horsburgh, K. (191) 205)

Seizures
κ-Opioid receptors; Glycine/NMDA receptors; NMDLA (N-methyl-DL-aspartate); NMDLA infusion (Singh, L. (191) 477)

Sennosides
Rhein; Rheinanthrone; Histamine; Colon (rat) (Autore, G. (191) 97)

SK&F 38393
Dopamine D_1 receptors; Dopamine D_2 receptors; Behavioral effects; Bombesin; Eticlopride; SCH 23390; PPHT (2-(N-phenethyl-N-propyl)amino-5-hydroxytetralin); Grooming behaviour; Locomotion (Merali, Z. (191) 281)

Amphetamine; Ascorbate; GBR-12909; Neostriatum; Quinpirole; Voltammetry (in vivo) (Pierce, R.C. (191) 295)

Smooth muscle
Nitroprusside; Isoprenaline; cGMP; cAMP; Aorta (rat) (Maurice, D.H. (191) 471)

Smooth muscle (cerebrovascular)
Second messengers; Forskolin; Phorbol 12,13-dibutyrate; Pial vessels; (In vitro pharmacology) (Horsburgh, K. (191) 205)

Smooth muscle tone
Endothelin; Atriopeptin III; Methoxamine; Aorta; (Rabbit) (Opgenorth, T.J. (191) 351)

Smooth muscle (vascular)
Endotoxin; Ca^{2+}; L-Arginine pathway (Gray, G.A. (191) 89)

Prostaglandin $F_{2\alpha}$-induced contractions; Thromboxane receptor antagonists; Coronary artery (Nakajima, M. (191) 359)

Somatostatin release
Galanin; Rin-m cells; G-proteins (guanine nucleotide-binding proteins) (Amiranoff, B. (191) 401)

Spinal cord
NMDA (N-methyl-D-aspartate); 7-Chlorokynurenic acid; HA-966; Glycine; Cortical wedge; (Electrophysiology) (Brugger, F. (191) 29)

Opioids; Flexor reflex; Spinal cord injury (Hao, J. (191) 407)

Spinal cord injury
Opioids; Spinal cord; Flexor reflex (Hao, J. (191) 407)

Spontaneously hypertensive rats (SHR)
CGRP (calcitonin gene-related peptide); Norepinephrine release; Medulla oblongata; Wistar-Kyoto rats (WKY) (Tsuda, K. (191) 101)

Striatum
Haloperidol (chronic); Dopamine; DOPAC (3,4-dihydroxyphenylacetic acid); (Endogenous release); (Ex vivo study) (Umeda, Y. (191) 149)

Pilocarpine; Convulsions; Dopamine D_1 receptors (Al-Tajir, G. (191) 329)

Substance P
Oedema; Nitric oxide (NO); Blood flow; Microvascular permeability (Hughes, S.R. (191) 481)

Synaptosomes (superfused)
NMDA (N-methyl-D-aspartate); Noradrenaline release; Hippocampus (rat); Glycine (Pittaluga, A. (191) 231)

Tail flicks (spontaneous)
5-HT (5-hydroxytryptamine, serotonin); 5-HT receptors; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin; ICI 169,369; Ritanserin; TFMPP (1-[3-(trifluoromethyl)phenyl]-piperazine); DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); (Rat) (Bervoets, K. (191) 185)

TFMPP (1-[3-(trifluoromethyl)phenyl]piperazine)
5-HT (5-hydroxytryptamine, serotonin); 5-HT receptors; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin; ICI 169,369; Ritanserin; Tail flicks (spontaneous); DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); (Rat) (Bervoets, K. (191) 185)

Thromboxane B_2
Leukotriene B_4; Prostaglandin E_2; Indobufen; Platelet cyclooxygenase (Patrignani, P. (191) 83)

Thromboxane receptor antagonists
Prostaglandin $F_{2\alpha}$-induced contractions; Smooth muscle (vascular); Coronary artery (Nakajima, M. (191) 359)

Timolol
Propranolol; Ethanol lesions; Indomethacin; Prostaglandin release; Membrane stabilising action (Bhandare, P. (191) 167)

U-50,488H
Opioids; Formalin; Antinociception (Haley, J. (191) 437)

Uptake inhibition
p-Chloroamphetamine; 1-(4-Chlorophenyl)-2-aminobutane (CAB); Drug discrimination; Microdialysis in vivo; 5-HT neurotoxicity (Johnson, M.P. (191) 1)

Uptake sites
Norepinephrine; [^{3}H]Nisoxetine (Tejani-Butt, S.M. (191) 239)

Use-dependent block
Conduction velocity; Bunazosin; α_1-Adrenoceptor antagonists; Antiarrhythmic effect (Hasegawa, J. (191) 369)

Uterus (human)
Oxytocin receptors; Vasopressin receptors; Vasopressin analogues (radiolabelled); Oxytocin analogues (radiolabelled); Pregnancy (Tence, M. (191) 427)

Vascular injury
Endotoxin; Nitric oxide (NO); Nitro-vasodilators; N^G-Monomethyl-L-arginine (L-NMMA) (Boughton-Smith, N.K. (191) 485)

Vas deferens (rat)
β-Adrenoceptors; Functional antagonism; Agonist dissociation constant; Efficacy (relative) (Diaz-Toledo, A. (191) 157)

Vasoactive intestinal polypeptide (VIP)
Gastric fundus (rat); N^G-Monomethyl-L-Arginine (L-NMMA); L-arginine; Nitric oxide; Non-adrenergic, non-cholinergic transmission (Li, C.G. (191) 303)

Insulin secretion; Glucagon secretion; Peptide receptor antagonists; Gastrin-releasing peptide (GRP); Cholecystokinin (CCK); (Mouse); (In vivo) (Karlsson, S. (191) 457)

Vasoconstriction
Facial vein (simian); Cannula insertion method; Acetylcholine; Muscarinic receptor subtypes (Chiba, S. (191) 311)

Bronchoconstriction; Endothelin; Heart; Lung; Endothelin receptors (Hemsén, A. (191) 319)

Vasodilators
Ligustrazine; Pulmonary artery; Bronchial artery; (Human) (Liu, S. (191) 345)

Vasopressin
EGF (epidermal growth factor-urogastrone); Ciliary muscle; Prostaglandin E_1 (Yamaguchi, K. (191) 245)

Vasopressin analogues (radiolabelled)
Uterus (human); Oxytocin receptors; Vasopressin receptors; Oxytocin analogues (radiolabelled); Pregnancy (Tence, M. (191) 427)

[Arg^8]vasopressin (AVP)
Aminoglycosides; Adenosine 3′,5′-cyclic monophosphate; Collecting tubule; Henle's loop (thick ascending limb of) (Kidwell, D. (191) 489)

Vasopressin receptors
Uterus (human); Oxytocin receptors; Vasopressin analogues (radiolabelled); Oxytocin analogues (radiolabelled); Pregnancy (Tence, M. (191) 427)

Vasorelaxation
Adenylate cyclase-cyclic AMP system; Precontraction levels; Methoxamine; (Canine veins) (Tsuru, H. (191) 447)

Voltammetry (in vivo)
Amphetamine; Ascorbate; GBR-12909; Neostriatum; Quinpirole; SK&F 38393 (Pierce, R.C. (191) 295)

Wistar-Kyoto rats (WKY)
CGRP (calcitonin gene-related peptide); Norepinephrine release; Medulla oblongata; Spontaneously hypertensive rats (SHR) (Tsuda, K. (191) 101)

Yohimbine
Cerebral artery (bovine); Adrenoceptor function (heterogeneity of); Prazosin; α_1-Adrenoceptors (Ayajiki, K. (191) 417)